• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ultralife Corporation to Acquire Electrochem Solutions, Inc.

    9/30/24 8:00:00 AM ET
    $ITGR
    $ULBI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Industrial Machinery/Components
    Miscellaneous
    Get the next $ITGR alert in real time by email

    NEWARK, N.Y., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) has signed a stock purchase agreement to acquire all outstanding shares of Electrochem Solutions, Inc. ("Electrochem") to include its state-of-the-art ISO certified technology and manufacturing facility for $50.0 million in cash from Integer Holdings Corporation (NYSE:ITGR), subject to customary working capital adjustments. The transaction is expected to close by the end of October. Ultralife expects to finance the transaction through its primary lender.

    Based in Raynham, MA and with over forty years of battery technology experience in critical applications, Electrochem designs and manufactures primary lithium metal and ultracapacitor cells and battery packs serving energy, military and various environmental, industrial and utility end markets on a global basis. For the trailing twelve-month period ended June 30, 2024, Electrochem recorded revenue of $34 million. The transaction is expected to be accretive on an EPS basis for 2025.

    "Acquiring Electrochem advances our strategy of more fully realizing the operating leverage of our business model through scale and manufacturing cost efficiencies," said Mike Manna, President and Chief Executive Officer. "Electrochem brings a blue-chip customer base with little or no overlap with Ultralife's customers, long-tenured technical resources which we plan to utilize in progressing our global new product initiatives, and a complimentary portfolio of highly-engineered thionyl, sulfuryl and bromine chloride cells and packs which can be commercially cost prohibitive to substitute or switch out. Therefore, we view this acquisition as an avenue to create highly attractive opportunities to drive revenue growth through heightened cross-selling platforms and extend our reach into underserved adjacent markets that demand uncompromised safety, service, reliability and quality. In addition, the combination of Electrochem and Ultralife creates achievable opportunities for gross margin expansion through the realization of vertical integration, supply chain synergies and lean initiatives. Finally, with Electrochem we are increasing our value to our customers and significantly strengthening our competitive position in our end markets."

    Added Mr. Manna, "Acquisitions have been and remain an important component of our growth strategy and with our leverage at a manageable level this year, we stepped up our efforts to identify high quality acquisition candidates that would fit with our innovative and technology focused culture and market expansion strategy. Electrochem checks the boxes that are most important to us, and we are delighted that Khristine Carroll will join us as Senior Vice President - General Manager of Electrochem upon closing. She is a dynamic, seasoned executive who has been the driving force in expanding Electrochem's commercial reach and strategy, while improving operational and supply chain efficiencies and enhancing the corporate culture since she joined in May 2023. We look forward to her contributions to Ultralife's growth across our diverse Battery & Energy Products business. We are prepared to begin implementing our integration playbook immediately upon closing the transaction and look forward to welcoming the Electrochem team to Ultralife."

    "Electrochem is well known and respected among its long-standing customer base for our consistently reliable, innovative and high quality domestically sourced battery solutions," said Khristine Carroll, General Manager of Electrochem Solutions, Inc. "In joining Ultralife Corporation, we will be able to enhance our product offerings, and customer-based support through a wider range of products and services, while continuing to focus on technology enhancements and advancements to innovation. This will afford us opportunities for continued growth to include further support to successfully deliver current 2025 revenue and profitability plans. We are thrilled to have found a partner that shares our operating philosophy and strong commitment to both our associates as well as our valued customers."

    About Ultralife Corporation

    Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe. Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

    This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions or delays in our supply of raw materials and components due to business conditions, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

    Company Contact:Investor Relations Contact:
    Ultralife CorporationLHA
    Philip A. Fain Jody Burfening
    (315) 210-6110(212) 838-3777
    [email protected] [email protected] 


    Primary Logo

    Get the next $ITGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ITGR
    $ULBI

    CompanyDatePrice TargetRatingAnalyst
    Integer Holdings Corporation
    $ITGR
    10/24/2025Buy → Hold
    Argus
    Integer Holdings Corporation
    $ITGR
    10/24/2025$80.00Overweight → Equal Weight
    Wells Fargo
    Integer Holdings Corporation
    $ITGR
    10/24/2025$77.00Buy → Neutral
    Citigroup
    Integer Holdings Corporation
    $ITGR
    10/24/2025$87.00Buy → Neutral
    BofA Securities
    Integer Holdings Corporation
    $ITGR
    10/24/2025Buy → Hold
    The Benchmark Company
    Integer Holdings Corporation
    $ITGR
    5/22/2025$140.00Neutral → Buy
    Citigroup
    Integer Holdings Corporation
    $ITGR
    3/28/2025$145.00Outperform
    Raymond James
    Integer Holdings Corporation
    $ITGR
    2/21/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ITGR
    $ULBI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Corporate Controller Thomas Tommy P converted options into 795 shares and covered exercise/tax liability with 334 shares, increasing direct ownership by 13% to 4,057 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    1/21/26 8:53:09 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Global Ops and Manufactur Harris John A covered exercise/tax liability with 552 shares and converted options into 1,148 shares, increasing direct ownership by 10% to 6,662 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    1/21/26 8:52:27 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Chief Financial Officer Smith Diron converted options into 3,360 shares and covered exercise/tax liability with 920 shares, increasing direct ownership by 32% to 10,138 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    1/21/26 8:51:49 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    $ULBI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ITGR
    $ULBI
    SEC Filings

    View All

    $ITGR
    $ULBI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ITGR
    $ULBI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Integer to Highlight Integrated R&D Solutions and Expanded Coating Capabilities During MD&M West 2026

    PLANO, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will exhibit during MD&M West 2026 in Anaheim, Calif., Feb. 3 – 5. Integer will unveil a significantly expanded 20 x 50 sq. ft. new booth #3201, showcasing the company's full range of customer solutions. On prominent display will be R&D Velocity, Integer's integrated R&D ecosystem connecting design, prototyping and manufacturing to help medical device companies develop products that are manufacturable from the start, accelerating the time between design and manufacturability. "Whether you're

    1/28/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Announces Conference Call to Discuss Fourth Quarter and Full Year 2025 Results

    PLANO, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the fourth quarter and year ended Dec. 31, 2025, on Thursday, Feb. 19, 2026, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the fourth quarter and full year on Feb. 19 prior to the conference call. Conference call details: Date: Thursday, Feb. 19, 2026Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 30

    1/22/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer to Showcase Innovations in Neuromodulation, Miniaturized Active Implantable Device Technology During NANS 2026 Annual Meeting

    PLANO, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) --  Integer Holdings Corporation (NYSE:ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will join global medtech leaders and innovators in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting in Las Vegas from Jan. 22 – 25, 2026. At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to accelerate development timelines and reduce risk for medical device companies bringing novel therapies to market. "Miniaturization is tra

    1/14/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ultralife Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ULTRALIFE CORP (0000875657) (Filer)

    11/18/25 7:30:23 AM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    SEC Form 10-Q filed by Ultralife Corporation

    10-Q - ULTRALIFE CORP (0000875657) (Filer)

    11/17/25 5:26:48 PM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    SEC Form NT 10-Q filed by Ultralife Corporation

    NT 10-Q - ULTRALIFE CORP (0000875657) (Filer)

    11/7/25 2:14:55 PM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    Integer Holdings downgraded by Argus

    Argus downgraded Integer Holdings from Buy to Hold

    10/24/25 2:15:30 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Integer Holdings from Overweight to Equal Weight and set a new price target of $80.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Citigroup with a new price target

    Citigroup downgraded Integer Holdings from Buy to Neutral and set a new price target of $77.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Whitmore Bradford T bought $300,902 worth of shares (53,000 units at $5.68) (SEC Form 4)

    4 - ULTRALIFE CORP (0000875657) (Issuer)

    12/16/25 4:32:26 PM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    Director Goddard Janie bought $9,999 worth of Common Stock; $.10 par value (1,739 units at $5.75), increasing direct ownership by 29% to 7,668 units (SEC Form 4)

    4 - ULTRALIFE CORP (0000875657) (Issuer)

    12/15/25 4:10:29 PM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    Director Robert W. Shaw bought $9,922 worth of Common Stock; $.10 par value (1,750 units at $5.67), increasing direct ownership by 3% to 71,000 units (SEC Form 4)

    4 - ULTRALIFE CORP (0000875657) (Issuer)

    11/26/25 9:58:19 AM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    $ITGR
    $ULBI
    Leadership Updates

    Live Leadership Updates

    View All

    Payman Khales Assumes Role as Integer President and CEO

    ~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company's Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as Preside

    10/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Appoints Michael Coyle to Board of Directors

    ~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Bef

    7/10/25 4:52:01 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ultralife Corporation Expands Leadership Team to Drive Rapid Growth Plans

    NEWARK, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) today announced the appointment of Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President - Sales & Business Development, Battery & Energy Products, effective January 6, 2025. As Chief Marketing Officer, Jeff will be responsible for reframing our corporate and brand strategies, providing alignment and accountability throughout the global organization. He will collaborate closely with our sales and engineering teams to develop and execute effective go-to-market strategies, ensuring that Ultralife's products and solutions meet the evolving needs of our customers. Jeff brings over two

    1/6/25 7:00:00 AM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    $ITGR
    $ULBI
    Financials

    Live finance-specific insights

    View All

    Integer Announces Conference Call to Discuss Fourth Quarter and Full Year 2025 Results

    PLANO, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the fourth quarter and year ended Dec. 31, 2025, on Thursday, Feb. 19, 2026, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the fourth quarter and full year on Feb. 19 prior to the conference call. Conference call details: Date: Thursday, Feb. 19, 2026Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 30

    1/22/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ultralife Corporation Reports Third Quarter Results

    NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results: Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5%Gross profit of $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the third quarter of 2024Operating loss of $1.0 million, reflecting one-time non-recurring costs of $1.1 million, including a $.5 million provision to close our Calgary facility, compared to operating income of $0.5 million for the third quarter of 2024GAAP EP

    11/18/25 7:00:00 AM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    Ultralife Corporation to Report Third Quarter Results on November 18, 2025

    NEWARK, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2025 before the market opens on Tuesday, November 18, 2025. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 18, 2025.   Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call:   https://register-conf.media-server.com/register/BI0301fd92021249ef830e0c9c7b

    11/13/25 4:30:00 PM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    $ITGR
    $ULBI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Ultralife Corporation

    SC 13D/A - ULTRALIFE CORP (0000875657) (Subject)

    9/3/24 4:15:14 PM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G filed by Ultralife Corporation

    SC 13G - ULTRALIFE CORP (0000875657) (Subject)

    2/14/24 1:50:40 PM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G/A filed by Ultralife Corporation (Amendment)

    SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)

    2/9/24 9:59:17 AM ET
    $ULBI
    Industrial Machinery/Components
    Miscellaneous